CytRx Corp. (CYTR) Hits Patient Enrollment Target in Phase II Clinical Trial for Tamibarotene
CytRx is a biopharmaceutical research and development company specializing in oncology. The company’s current oncology pipeline includes two programs in clinical development for cancer indications, aldoxorubicin, and tamibarotene. It also completed evaluation of a third drug candidate, bafetinib, and is seeking a partner for further development of the drug. The company reported today that enrollment of 140 evaluable patients has been completed in its global Phase 2b clinical trial with CytRx’s oral retinoid compound tamibarotene in combination with chemotherapeutic agents. Tamibarotene was developed to be superior to ATRA, an FDA-approved retinoid, by binding to its molecular target more selectively. The…